- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00498706
Effectiveness of Telephone Versus Face-to-Face CBT in Treating People With Depression
Telephone Versus Face-to-Face Administration of CBT for Depression
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Major depressive disorder is a common and often long-lasting disorder with 12-month prevalence rates estimated to be between 6.6% and 10.3%. Although the personal and societal costs of depression are high, it is well established that depression can be effectively treated using antidepressant medication and/or forms of psychotherapy. Several studies have found that when given a choice, about two-thirds of depressed patients prefer psychotherapy or counseling over antidepressant medication. However, a variety of barriers exist to initiating and maintaining psychotherapy. Only about 20% of all patients referred for psychotherapy actually initiate treatment, and of those who do initiate treatment, nearly half drop out before completing treatment. The use of the telephone to deliver treatment services has been recommended as a way to reduce many of the barriers associated with failure to initiate and sustain treatment. When administered over the telephone, cognitive behavioral therapy (CBT), a form of psychotherapy that teaches ways to modify thoughts and behaviors that contribute to depression, may be superior to face-to-face CBT in improving treatment adherence and reducing depressive symptoms. This study will compare the effectiveness of telephone CBT (T-CBT) versus face-to-face CBT (FtF-CBT) in treating people with depression.
Participation in this study will include 18 weeks of treatment and 12 months of follow-up. All participants will first undergo baseline assessments that will include a telephone interview and questionnaires about mood. Participants will then be assigned randomly to receive T-CBT or FtF-CBT. Participants in both groups will receive eighteen 45-minute sessions of their assigned treatment over 18 weeks. Sessions will occur twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. During sessions, participants will learn ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made. Treatment sessions will be identical for both groups, except one group will receive sessions over the telephone and the other in-person at a study office. All participants will repeat the baseline assessments at Weeks 4, 9, 14, and 18 of treatment and Months 3, 6, 9, and 12 of follow-up.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Northwestern University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Has a current diagnosis of major depressive disorder
- Has a primary care physician at Northwestern University in Illinois, or one of a number of approved community clinics in Chicago.
- Resides in Illinois
- Has a telephone
- Speaks and reads English
Exclusion Criteria:
- Hearing, voice, or visual impairment
- Meets criteria for dementia
- Diagnosed with a psychotic disorder, bipolar disorder, dissociative disorder, current substance abuse, or other condition for which participation in a clinical trial of psychotherapy may be either inappropriate or dangerous
- Currently receiving individual psychotherapy or planning to receive psychotherapy during the treatment phase of the study
- Planning to be out of town or unavailable for treatment for 4 weeks or more during the scheduled treatment time
- Recent history of suicide attempts or is severely suicidal
- Initiated treatment with an antidepressant in the 2 months before study entry (antidepressant medication is not exclusionary)
- Depression determined to be primarily of an organic etiology
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Telephone-administered CBT
Participants will receive telephone-administered cognitive behavioral therapy.
|
Over 18 weeks, participants will receive eighteen 45-minute sessions of T-CBT administered by a therapist.
Participants will undergo telephone-administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks.
Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
|
Comparatore attivo: Face-to-face CBT
Participants will receive face-to-face cognitive behavioral therapy.
|
Over 18 weeks, participants will receive eighteen 45-minute sessions of FtF-CBT administered by a therapist.
Participants will undergo face-to-face administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks.
Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Attrition (Number of Therapy Sessions Attended)
Lasso di tempo: Post treatment, up to 18 weeks
|
Number of therapy sessions attended was collected.
At the end of treatment, the total number of sessions attended by each patient was collected.
|
Post treatment, up to 18 weeks
|
Number of Participants Who Dropped Out of Therapy
Lasso di tempo: Post treatment, up to 18 weeks
|
Using the number of therapy sessions attended, we categorized patients into:
|
Post treatment, up to 18 weeks
|
Patient Health Questionnaire (PHQ)-9
Lasso di tempo: Measured at baseline; Weeks 4, 9, 14, and 18; and Months 3, 6 post-treatment follow-up
|
Measures depression on a 9 - item scale.
Scores range from 0-27, with 0 being no symptoms.
A difference of 5 or more points on the PHQ-9 is considered a clinically meaningful response to treatment.
|
Measured at baseline; Weeks 4, 9, 14, and 18; and Months 3, 6 post-treatment follow-up
|
Depression, as Assessed by Hamilton Depression Rating Scale(Ham-D)
Lasso di tempo: Measured at baseline; Weeks 4, 9, 14, and 18; and Months 3, 6, 9, and 12 of follow-up
|
Ham-D indicates Hamilton Depression Rating Scale,range is 0 to 52.
A score of 0 means the best outcome with no depression symptoms reported, and a score of 52 is the worse outcome with highest level of depression reported.
A difference of 3 points on the Hamilton scale has been identified as clinically significant.
|
Measured at baseline; Weeks 4, 9, 14, and 18; and Months 3, 6, 9, and 12 of follow-up
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Health-related Quality of Life (SF-36V), Patient Satisfaction (Satisfaction Index - Mental Health), and Therapeutic Alliance (Working Alliance Inventory - Short Form)
Lasso di tempo: Measured at baseline; Weeks 4, 9, 14, and 18; and Months 3, 6, 9, and 12 of follow-up
|
Measured at baseline; Weeks 4, 9, 14, and 18; and Months 3, 6, 9, and 12 of follow-up
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: David C. Mohr, PhD, Northwestern University
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- R01MH059708 (Sovvenzione/contratto NIH degli Stati Uniti)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Telephone-administered cognitive behavioral therapy (T-CBT)
-
Ontario Shores Centre for Mental Health SciencesMindbeaconRitiratoDisturbo depressivo maggiore